Stocks · News reference
Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate
Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:15 PM
- Checked
- Aug 17, 2026, 12:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Nasus Pharma Ltd. (NYSE: NSRX) announced the appointment of Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. O'Grady, a pharmaceutical industry veteran with 35 years of experience and former CEO of Teva USA, will lead the company's growth strategy with focus on commercializing NS002, an intranasal epinephrine treatment for anaphylaxis targeting a $2 billion market opportunity. He succeeds Dan Teleman in the leadership transition.
Read original at globenewswire-incNasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the
Read original at benzinga